Display options
Cite
Gaudet MM, Patel AV, Teras LR, et al. Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int J Mol Epidemiol Genet. 2013;4(3):156-66
Gaudet, M. M., Patel, A. V., Teras, L. R., Sun, J., Campbell, P. T., Stevens, V. L., Jacobs, E. J., & Gapstur, S. M. (2013). Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. International journal of molecular epidemiology and genetics, 4(3), 156-66.
Gaudet, Mia M, et al. "Obesity-related markers and breast cancer in CPS-II Nutrition Cohort." International journal of molecular epidemiology and genetics vol. 4,3 (2013): 156-66.
Gaudet MM, Patel AV, Teras LR, Sun J, Campbell PT, Stevens VL, Jacobs EJ, Gapstur SM. Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int J Mol Epidemiol Genet. 2013 Sep 12;4(3):156-66. eCollection 2013. PMID: 24046808; PMCID: PMC3773567.
Copy Download .nbib Format: NLM
Share it on

Int J Mol Epidemiol Genet. 2013 Sep 12;4(3):156-66. eCollection 2013.

Obesity-related markers and breast cancer in CPS-II Nutrition Cohort.

International journal of molecular epidemiology and genetics

Mia M Gaudet, Alpa V Patel, Lauren R Teras, Juzhong Sun, Peter T Campbell, Victoria L Stevens, Eric J Jacobs, Susan M Gapstur

Affiliations

  1. Epidemiology Research Program, American Cancer Society Atlanta, GA, USA.

PMID: 24046808 PMCID: PMC3773567

Abstract

Low circulating levels of adiponectin and high levels of insulin-like growth factor-1 (IGF-1), C-reactive protein (CRP), and C-peptide have been shown to be related to postmenopausal breast cancer risk, and to partially mediate the obesity-postmenopausal breast cancer association; however, data from prospective studies, especially those limited to non-users of postmenopausal hormones, are sparse. To further evaluate these associations, we measured these markers in a case-control study nested in the Cancer Prevention Study-II (CPS-II) Nutrition Cohort. Plasma samples from 302 postmenopausal breast cancer cases and matched controls were analyzed. None of the women were taking postmenopausal hormones at blood draw. Multivariable-adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression models. Low levels of total adiponectin and high levels of total IGF-1 and CRP were associated with increased breast cancer risk, but associations were not statistically significant. The association with C-peptide was statistically significant (T3 vs. T1: OR=1.63, 95% CI 1.08-2.45; p-value for linear trend=0.001), but was slightly attenuated after further adjustment for BMI (T3 vs. T1: OR=1.51, 95% CI 0.99-2.31; p-value for linear trend=0.004). The association between BMI and breast cancer risk was attenuated toward the null after controlling for C-peptide (from OR=1.43 to OR=1.25 for BMI ≥30 kg/m(2) compared to <25 kg/m>(2)). The elevated risk of postmenopausal breast cancer associated with higher circulating levels of C-peptide is consistent with a role of hyperinsulinemia in breast carcinogenesis, and might account for some of the higher risk associated with obesity.

Keywords: Breast cancer; C-peptide; obesity; risk

References

  1. Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):220-4 - PubMed
  2. J Emerg Med. 1999 Nov-Dec;17(6):1019-25 - PubMed
  3. Clin Chem. 2001 Mar;47(3):444-50 - PubMed
  4. Int J Cancer. 2006 Aug 1;119(3):659-67 - PubMed
  5. Eur J Cancer Prev. 2014 Mar;23(2):76-83 - PubMed
  6. Lancet Oncol. 2010 Jun;11(6):530-42 - PubMed
  7. Cancer Causes Control. 2002 Oct;13(8):741-51 - PubMed
  8. Am J Epidemiol. 1993 Jan 15;137(2):235-41 - PubMed
  9. Diabetes Metab Rev. 1994 Jul;10(2):91-117 - PubMed
  10. Int J Cancer. 2007 Aug 15;121(4):856-62 - PubMed
  11. Mol Med. 2008 Nov-Dec;14(11-12):741-51 - PubMed
  12. Int J Cancer. 2006 Jun 1;118(11):2832-9 - PubMed
  13. Nat Rev Cancer. 2008 Dec;8(12):915-28 - PubMed
  14. Horm Res. 2008;69(5):295-300 - PubMed
  15. Cancer Epidemiol. 2010 Oct;34(5):580-6 - PubMed
  16. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2117-25 - PubMed
  17. J Clin Invest. 1978 Jul;62(1):197-203 - PubMed
  18. J Natl Cancer Inst. 2009 Jan 7;101(1):48-60 - PubMed
  19. J Clin Endocrinol Metab. 2007 Apr;92(4):1510-6 - PubMed
  20. Br J Cancer. 2008 Oct 21;99(8):1246-50 - PubMed
  21. Crit Rev Clin Lab Sci. 1984;19(4):297-352 - PubMed
  22. Endocrinology. 1990 Nov;127(5):2418-22 - PubMed
  23. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1361-8 - PubMed
  24. Cancer Causes Control. 2009 Feb;20(1):15-26 - PubMed
  25. J Clin Endocrinol Metab. 1993 Oct;77(4):976-81 - PubMed
  26. Nat Rev Cancer. 2004 Aug;4(8):579-91 - PubMed
  27. J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26 - PubMed
  28. Ann Clin Biochem. 1999 Sep;36 ( Pt 5):541-64 - PubMed
  29. Am J Clin Nutr. 2006 May;83(5):1106-11 - PubMed
  30. Cancer. 2002 May 1;94(9):2490-501 - PubMed
  31. J Clin Endocrinol Metab. 1997 Aug;82(8):2497-502 - PubMed
  32. N Engl J Med. 2003 Dec 4;349(23):2184-6 - PubMed
  33. Trends Endocrinol Metab. 2006 Oct;17(8):328-36 - PubMed
  34. Epidemiology. 2007 Nov;18(6):722-9 - PubMed
  35. Am J Epidemiol. 2002 Aug 15;156(4):349-52 - PubMed
  36. Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):161-4 - PubMed
  37. Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):972-8 - PubMed
  38. Metabolism. 1997 Jan;46(1):5-9 - PubMed
  39. Cancer Lett. 2007 Jun 8;250(2):229-36 - PubMed
  40. Breast Cancer Res Treat. 2009 Feb;113(3):567-76 - PubMed
  41. Nat Rev Cancer. 2004 Jul;4(7):505-18 - PubMed
  42. J Biol Chem. 2004 Mar 26;279(13):12152-62 - PubMed
  43. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):972-8 - PubMed
  44. Int J Cancer. 2000 Dec 1;88(5):828-32 - PubMed
  45. Cancer Causes Control. 2002 May;13(4):307-16 - PubMed
  46. Int J Cancer. 2007 Jun 15;120(12):2678-86 - PubMed
  47. Int J Cancer. 2004 Sep 20;111(5):762-71 - PubMed

Publication Types